Qi Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Qi Wang has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Da-Wei Kong
Peking University China-Japan Friendship School of Clinical Medicine, Beijing, China
2 shared publications - Ge-Le Aori
Peking University China-Japan Friendship School of Clinical Medicine, Beijing, China
2 shared publications - Li Zhang
Department of Neurosurgery, China-Japan Friendship Hospital, Chaoyang District, Beijing, China
2 shared publications - Lihe Zhang
State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, 38 Xueyuan Road, Beijing 100191, China
2 shared publications - Wenqiang Yang
Department of Neurosurgery, China-Japan Friendship Hospital, Beijing, China
2 shared publications - Zhuang-Li Guo
Department of Rehabilitation, The Affiliated Hospital of Qingdao University, Qingdao, China
2 shared publications
Latest Publications
- Open Access
- 14 January 2018
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2018 (1) , 5798453
Danhong Injection Alleviates Mechanical Allodynia via Inhibiting ERK1/2 Activation and Elevates BDNF Level in Sciatic Nerve in Diabetic Rat
Danhong injection (DHI) has been widely used in China for cardiocerebrovascular diseases treatments. And in this study, we demonstrated the therapeutic effect of DHI on experimental diabetic neuropathy for the first time. Methods. Streptozotocin‐ (STZ‐) induced SD rats were used. In experiment 1, 4‐week treatment with DHI or saline started 4 weeks after STZ injection; mechanical allodynia was measured before and every 2 weeks after STZ injection. In experiment 2, chronic intrathecal infusion of U0126 was conducted during the 8th week of diabetes. Phosphorylated and total ERK1/2 in spinal cord were analyzed by western blot. BDNF level in sciatic nerve was evaluated by ELISA. Results. DHI treatment significantly alleviated mechanical allodynia at the end of the study and downregulated the expression of phosphorylated ERK1/2 in spinal cord. In addition, DHI treatment also elevated brain‐derived neurotrophic factor (BDNF) level in sciatic nerve of DPN rat. In experiment 2, inhibition of ERK1/2 activation was confirmed to result in the alleviation of mechanical allodynia. Conclusions. We demonstrated that DHI was able to alleviate mechanical allodynia in diabetic neuropathy rat through inhibiting the activation of ERK1/2. The reduction of BDNF content in sciatic nerve was also partially reversed by DHI treatment.
- 14 January 2018
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2018 (1) , 5798453
Open AccessDanhong Injection Alleviates Mechanical Allodynia via Inhibiting ERK1/2 Activation and Elevates BDNF Level in Sciatic Nerve in Diabetic Rat
Danhong injection (DHI) has been widely used in China for cardiocerebrovascular diseases treatments. And in this study, we demonstrated the therapeutic effect of DHI on experimental diabetic neuropathy for the first time. Methods. Streptozotocin‐ (STZ‐) induced SD rats were used. In experiment 1, 4‐week treatment with DHI or saline started 4 weeks after STZ injection; mechanical allodynia was measured before and every 2 weeks after STZ injection. In experiment 2, chronic intrathecal infusion of U0126 was conducted during the 8th week of diabetes. Phosphorylated and total ERK1/2 in spinal cord were analyzed by western blot. BDNF level in sciatic nerve was evaluated by ELISA. Results. DHI treatment significantly alleviated mechanical allodynia at the end of the study and downregulated the expression of phosphorylated ERK1/2 in spinal cord. In addition, DHI treatment also elevated brain‐derived neurotrophic factor (BDNF) level in sciatic nerve of DPN rat. In experiment 2, inhibition of ERK1/2 activation was confirmed to result in the alleviation of mechanical allodynia. Conclusions. We demonstrated that DHI was able to alleviate mechanical allodynia in diabetic neuropathy rat through inhibiting the activation of ERK1/2. The reduction of BDNF content in sciatic nerve was also partially reversed by DHI treatment.
- Open Access
- 1 January 2018
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2018 (1) , 2789847
Tanshinone IIA Attenuates Diabetic Peripheral Neuropathic Pain in Experimental Rats via Inhibiting Inflammation
Diabetic peripheral neuropathic pain (DPNP) is a common and intractable complication of diabetes. Conventional therapies are always not ideal; development of novel drugs is still needed to achieve better pain relief. Recent evidences have demonstrated that inflammation is involved in the onset and maintenance of DPNP. The anti‐inflammatory property of Tanshinone IIA (TIIA) makes it a promising candidate to block or alter the pain perception. This study was conducted to investigate whether TIIA could attenuate DPNP in streptozotocin‐ (STZ‐) induced rats model and its potential mechanisms. TIIA was administered to STZ‐induced diabetic rats at the dose of 40 mg/kg once a day for 3 weeks. The effects of TIIA on thermal hyperalgesia and mechanical allodynia were investigated using behavioral tests. The mRNA level and expression of interleukin‐ (IL‐) 1β, interleukin‐ (IL‐) 6, tumor necrosis factor‐ (TNF‐) α, and interleukin‐ (IL‐) 10 in the fourth to sixth segments of the dorsal root ganglion (L4–6 DRG) were detected by quantitative real‐time PCR (qPCR) and Western blot. TIIA treatment significantly attenuated mechanical allodynia and thermal hyperalgesia in diabetic rats. In addition, the expression of the proinflammatory cytokines IL‐1β, IL‐6, and TNF‐α was inhibited, and the level of the anti‐inflammatory cytokine IL‐10 was increased by TIIA. This study demonstrated that TIIA has significant antiallodynic and antihyperalgesic effects in a rat model of STZ‐induced DPNP, and the effect may be associated with its anti‐inflammation property.
- 1 January 2018
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2018 (1) , 2789847
Open AccessTanshinone IIA Attenuates Diabetic Peripheral Neuropathic Pain in Experimental Rats via Inhibiting Inflammation
Diabetic peripheral neuropathic pain (DPNP) is a common and intractable complication of diabetes. Conventional therapies are always not ideal; development of novel drugs is still needed to achieve better pain relief. Recent evidences have demonstrated that inflammation is involved in the onset and maintenance of DPNP. The anti‐inflammatory property of Tanshinone IIA (TIIA) makes it a promising candidate to block or alter the pain perception. This study was conducted to investigate whether TIIA could attenuate DPNP in streptozotocin‐ (STZ‐) induced rats model and its potential mechanisms. TIIA was administered to STZ‐induced diabetic rats at the dose of 40 mg/kg once a day for 3 weeks. The effects of TIIA on thermal hyperalgesia and mechanical allodynia were investigated using behavioral tests. The mRNA level and expression of interleukin‐ (IL‐) 1β, interleukin‐ (IL‐) 6, tumor necrosis factor‐ (TNF‐) α, and interleukin‐ (IL‐) 10 in the fourth to sixth segments of the dorsal root ganglion (L4–6 DRG) were detected by quantitative real‐time PCR (qPCR) and Western blot. TIIA treatment significantly attenuated mechanical allodynia and thermal hyperalgesia in diabetic rats. In addition, the expression of the proinflammatory cytokines IL‐1β, IL‐6, and TNF‐α was inhibited, and the level of the anti‐inflammatory cytokine IL‐10 was increased by TIIA. This study demonstrated that TIIA has significant antiallodynic and antihyperalgesic effects in a rat model of STZ‐induced DPNP, and the effect may be associated with its anti‐inflammation property.
- 1 April 2014
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 77, 258-268
Development of bivalent oleanane-type triterpenes as potent HCV entry inhibitors
- 1 April 2014
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 77, 258-268
Development of bivalent oleanane-type triterpenes as potent HCV entry inhibitors
- 1 September 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 20 (18) , 5616-5622
Conjugation of cyclodextrin with fullerene as a new class of HCV entry inhibitors
- 1 September 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 20 (18) , 5616-5622
Conjugation of cyclodextrin with fullerene as a new class of HCV entry inhibitors